ACRV - Acrivon Therapeutics, Inc.
1.88
-0.030 -1.596%
Share volume: 877,684
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.91
-0.03
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-13-2024 | 03-27-2025 | 05-14-2025 | 11-13-2025 | 03-19-2026 | |
| Assets | ||||||||
| Total Assets | 120.521 M | 230.585 M | 214.684 M | 196.588 M | 176.349 M | 145.299 M | 129.717 M | |
| Current Assets | 112.143 M | 182.358 M | 188.984 M | 181.629 M | 151.327 M | 130.361 M | 120.445 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 85.368 M | 134.531 M | 144.038 M | 139.662 M | 110.481 M | 93.849 M | 77.083 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 24.607 M | 46.006 M | 43.415 M | 39.818 M | 39.154 M | 35.405 M | 41.499 M | |
| Total Non-current Assets | 0.000 | 39.895 M | 15.390 M | 5.089 M | 15.195 M | 5.108 M | 0.000 | |
| Property Plant Equipment | 3.408 M | 3.467 M | 4.670 M | 4.471 M | 4.676 M | 5.189 M | 4.889 M | |
| Other Assets | 4.970 M | 44.760 M | 21.030 M | 10.488 M | 20.346 M | 9.749 M | 4.383 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 120.521 M | 230.585 M | 214.684 M | 196.588 M | 176.349 M | 145.299 M | 129.717 M | |
| Total liabilities | 12.542 M | 14.527 M | 17.792 M | 19.802 M | 15.959 M | 16.696 M | 17.201 M | |
| Total current liabilities | 9.041 M | 11.284 M | 14.819 M | 17.214 M | 13.550 M | 14.891 M | 15.664 M | |
| Accounts Payable | 2.056 M | 1.261 M | 1.506 M | 758.000 K | 3.691 M | 996.000 K | 2.277 M | |
| Other liabilities | 3.501 M | 3.243 M | 2.973 M | 2.588 M | 2.409 M | 1.805 M | 1.537 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 3.501 M | 3.243 M | 2.973 M | 2.588 M | 2.409 M | 1.805 M | 1.537 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 107.979 M | 216.058 M | 196.892 M | 176.786 M | 160.390 M | 128.603 M | 112.516 M | |
| Common stock | 240.955 M | 367.781 M | 370.255 M | 373.315 M | 376.763 M | 384.387 M | 387.286 M | |
| Retained earnings | -132.906 M | -151.704 M | -174.145 M | -196.976 M | -216.656 M | -255.896 M | -274.881 M |